Clinical Trial Update: A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of R935788 for Warm Antibody Autoimmune Hemolytic Anemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Warm Antibody Autoimmune Hemolytic Anemia

Drugs mentioned

• R935788

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Warm Antibody Autoimmune Hemolytic Anemia | Phase 2 | Status: COMPLETED